TREATMENT BENEFITS ASSOCIATED WITH OPEN LABEL ORAL TREPROSTINIL AFTER CLINICAL WORSENING IN THE PHASE 3 FREEDOM-EV STUDY FOR THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION

Autor:	R. Grover, Carlos Jerjes-Sánchez, Kuo Wang, Victor F. Tapson, Tomás Pulido, Robert E. White, Ekkehard Grünig, Aliou Ousmanou, Derek Solum, Gisela Meyer, Pabo Sepulveda, Chunqin Deng
Rok vydání:	2019
Předmět:	Pulmonary and Respiratory Medicine medicine.medical_specialty business.industry Internal medicine Cardiology Medicine Open label Cardiology and Cardiovascular Medicine Critical Care and Intensive Care Medicine business Treprostinil medicine.drug
Zdroj:	Chest. 156:A1178-A1179
ISSN:	0012-3692
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::f25bf9976aaa50eceab6045bd01881ca https://doi.org/10.1016/j.chest.2019.08.1070 Zobrazit plný text záznamu